Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b/2 study of siremadlin alone and with donor lymphocyte infusion after allogeneic stem cell transplant in high-risk acute myeloid leukemia
MOH_2022-09-05_011926Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of siremadlin in acute myeloid leukemia (AML) (2 arms), sponsored by Novartis. Started Aug 2022; status: active, not recruiting.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-09-05_011926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-05_011926.